Discover

SLXN
Silexion Therapeutics Corp
0.21
2 x 0.20
2 x 0.32
bid
ask
-
0.02
8.64%
2 @ 07:57 PM
0.21 -0.00 (2.28%)
Ytd-98.88%
1y-99.46%
0.21
day range
0.23
0.21
52 week range
40.00
Open0.23Prev Close0.23Low0.21High0.23Mkt Cap3.11M
Vol821.09KAvg Vol9.90MEPS-27.21P/EN/AForward P/E-3.95
Beta-0.11Short Ratio0.23Inst. Own8.15%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0750-d Avg0.60200-d Avg8.381yr Est9.00
Earning
DateForEstimateReportedSurprisesurprise %
2024-11-142024-090-18.27N/AN/A
2011-05-162011-030N/AN/AN/A
2011-03-082010-120N/AN/AN/A
2010-12-062010-090N/AN/AN/A
2010-09-032010-060N/AN/AN/A
2010-06-042010-030N/AN/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
2024-11-01Maxim GroupUpgradeBuy
Profile
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Wildcat Capital Management, LLC113.43K286.97K0.79%
2024-09-29HRT Financial LP10.00K25.29K0.07%
2024-09-29Virtu Financial LLC2.96K7.49K0.02%
2024-09-29Two Sigma Securities, LLC1.68K4.25K0.01%
2024-09-29UBS Group AG1.67K4.23K0.01%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-10-30Fidelity NASDAQ Composite Index Fund587.001.49K0.00%
Split
SplitDate
1 : 102026-05-29